Results 111 to 120 of about 36,163 (246)
Gene therapy for lysosomal storage diseases: Current clinical trial prospects. [PDF]
Kido J, Sugawara K, Nakamura K.
europepmc +1 more source
Prostate cancer remains a leading cause of male cancer death, yet screening cannot reliably identify aggressive disease, underscoring the need for tissue biomarkers. It is shown that primary tumors increase ER–plasma membrane junction signaling via STIM1/ORP5, whereas metastasis features their loss, Golgi dispersal, and rapid conversion of high‐mannose
Amanda J. Macke +14 more
wiley +1 more source
ABSTRACT Current therapies for Parkinson's disease (PD) fail to concurrently address α‐synuclein (α‐syn) aggregation and microglia‐mediated neuroinflammation. Herein, we engineer a near‐infrared‐II (NIR‐II) phototheranostic nanoplatform, CAG/FD1080@MM‐aTRPV4, for synergistic regulation of microglial function and real‐time monitoring of PD pathology. We
Hsuan Lo +9 more
wiley +1 more source
Redefining the Health Risk of Battery Materials Through a Biologically Transformed Metal Mixture
Inhaled NCM particles undergo lysosomal degradation, releasing complex ion mixtures that induce systemic impact. The impact is determined by a critical balance between antagonistic Ni‐Co interactions and synergistic Mn effects. To capture these complexities in risk assessment, we develop an IAI model, ensuring a more accurate quantitative risk ...
Ze Zhang +11 more
wiley +1 more source
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley +1 more source
Novel Fused Pyrazole Amide Analogs as Glucosylceramide Synthase Inhibitors for Treating Lysosomal Storage Diseases, Neurodegenerative Diseases, Cystic Diseases, and Cancer. [PDF]
Sabnis RW.
europepmc +1 more source
Nanozymes, as enzyme‐mimicking nanomaterials, exhibit unique catalytic properties for the treatment of liver diseases. By regulating redox homeostasis, modulating immune responses, and enabling targeted delivery, nanozymes overcome the limitations of natural enzymes.
Xiandi Meng +6 more
wiley +1 more source
Human, economic, and social impact of lysosomal storage diseases. [PDF]
Brignani E +9 more
europepmc +1 more source
ABSTRACT The ciliopathies are a group of genetic disorders caused by defective function of either the primary cilia (a large number) or the motile cilia (a much smaller number). These have been defined as diseases with mutations in genes encoding individual ciliary or cilia‐associated proteins.
Robert P. Erickson +1 more
wiley +1 more source
Nonimmune Hydrops Fetalis and Lysosomal Storage Diseases
Carlo Bellini
doaj +1 more source

